How Karius aims to transform the diagnosis of infections
Welcome to Pharma50Talks! Drug Discovery & Development has returned with this year’s edition of the Pharma50.
In this second episode, Pharma Editor Brian Buntz got a chance to sit down with Dr. Brad Perkins, Chief Medical Officer at Karius, who details how the company aims to transform the diagnosis of infections with a non-invasive liquid biopsy. Dr. Perkins talks about how the California startup aims to help establish a world where infectious disease is no longer a major human health threat. Brad also walks us through how Karius uses genomics and AI to enable rapid accurate diagnosis of more than a 1,000 infectious pathogens from one test, how he has seen the demand for infectious disease diagnostics evolve, how AI based diagnostics can have a broader impact on our fight against antimicrobial resistance, and much more!
Full recap of the discussion can be found, HERE
To view the rest of the features of this year’s Pharma50 such as:
– The 50 largest pharmaceutical companies in the world
– Pharma’s top 20 R&D spenders in 2021
– 50 of 2021’s best-selling pharmaceuticals
– The 15 best pharma companies to work for
– 10 leading pharma executives